|Table of Contents|

Retrospective comparative analysis on stereotactic body radiotherapy combinations with and without transcatheter arterial chemoembolization for unresectable colorectal liver metastases

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
94-99
Research Field:
Publishing date:

Info

Title:
Retrospective comparative analysis on stereotactic body radiotherapy combinations with and without transcatheter arterial chemoembolization for unresectable colorectal liver metastases
Author(s):
CHEN Xishan1; CHEN Haihui1; MO Qia2; WANG Guodong1
1.Department of Oncology，the Fourth Affiliated Hospital of Guangxi Medical University，Liuzhou Worker's Hospital，Guangxi Liuzhou 545005，China；2.Department of Oncology，the Second Affiliated Hospital of Guangxi University of Science and Technology，Guangxi Liuzhou 545005，China.
Keywords:
colorectal cancer; liver metastases; TACE; SBRT
PACS:
R735.3＋5
DOI:
10.3969/j.issn.1672-4992.2021.01.021
Abstract:
Objective：To evaluate and compare the efficacy and safety of stereotactic body radiotherapy combined with transcatheter arterial chemoembolization for unresectable colorectal liver metastases.Methods：Twenty-three unresectable colorectal liver metastases patients previously received first-line systemic chemotherapy treated with stereotactic body radiotherapy or combined with transcatheter arterial chemoembolization between January 2009 and May 2018 were reviewed.A total of 13 patients underwent stereotactic body radiotherapy alone(SBRT group)，and 10 patients underwent transcatheter arterial chemoembolization combined with stereotactic body radiotherapy(TACE-SBRT group).The response rates(RR)，disease control rates(DCR)，time to progress(TTP) and treatment-related complications were observed.The Kaplan-Meier method，log-rank test and Cox multivariate analyses were adopted to analyze median progression-free survival(mPFS)，median overall survival(mOS) in patients with unresectable colorectal liver metastases.Results：Similar rates of RR and DCR were observed for the SBRT and TACE-SBRT group，and the difference between the two groups was no statistically significant(P=0.685).TACE-SBRT group had a longer disease-free time，there was statistically significant difference(11.77 1.56 vs 25.40 5.81，P=0.019).The mPFS of TACE-SBRT group was superior to that of SBRT group(17.4 months vs 15.1 months，respectively，P<0.05)，but there was no statistically significant difference between mOS.Moreover，only 1 patient had 3-grade acute hepatic injury，which was recovered after treatment.Cox multivariate analyses found synchronous metastasis and CEA level at diagnosis of liver metastasis was identified as significant prognostic factors for mPFS and mOS(P<0．05)．Conclusion：Stereotactic body radiotherapy combinations with transcatheter arterial chemoembolization for unresectable colorectal liver metastases is a safe and effective method，suggesting an acceptable alternative therapy for patients with unresectable colorectal liver metastases，but should be further studied in a larger series.

References:

[1]BRAY F，FERLAY J，SOERJOMATARAM I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
[2]VAN CUTSEM E，NORDLINGER B，ADAM R，et al.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases［J］.Eur J Cancer，2006，42(14)：2212-2221.
[3]YOO PS，LOPEZ-SOLER RI，LONGO WE，et al.Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab［J］.Clin Colorectal Cancer，2006，6(3)：202-207.
[4]ADAMS RB，ALOIA TA，LOYER E，et al.Selection for hepatic resection of colorectal liver metastases：Expert consensus statement［J］.HPB(Oxford)，2013，15(2)：91-103.
[5]陈进宏，王祥宇.结直肠癌同时性肝转移的手术时机与术式选择［J］.中国实用外科杂志，2018，38(02)：179-182. CHEN JH，WANG XY.Choice of timing and approach for surgical treatment of synchronous colorectal liver metastases［J］.Chinese Journal of Practical Surgery，2018，38(02)：179-182.
[6]VAN CUTSEM E，CERVANTES A，NORDLINGER B，et al.Metastatic colorectal cancer：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up［J］.Ann Oncol，2014，25(3)：iii1-9.
[7]中国结直肠癌肝转移诊断和综合治疗指南(Ⅴ 2018)［J］.中华结直肠疾病电子杂志，2018，7(04)：302-314. Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastasis(2018 edition)［J］.Chinese Journal of Colorectal Diseases(Electronic Edition)，2018，7(04)：302-314.
[8]TAN HL，LEE M，VELLAYAPPAN BA，et al.Liver-directed therapies in colorectal cancer［J］.Curr Colorectal Cancer Rep，2018，14(5)：129-137.
[9]ZACHARIAS AJ，JAYAKRISHNAN TT，RAJEEV R，et al.Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases：A meta-analysis［J］.PLoS One，2015，10(10)：e0139940.
[10]MASSMANN A，RODT T，MARQUARDT S，et al.Transarterial chemoembolization(TACE) for colorectal liver metastases-current status and critical review［J］.Langenbecks Arch Surg，2015，400(6)：641-659.
[11]TAKEDA A，SANUKI N，KUNIEDA E.Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer［J］.World J Gastroenterol，2014，20(15)：4220-4229.
[12]NUYTTENS JJ，VAN DER VOORT VAN ZYP NC，PRAAG J，et al．Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors［J］.Radiother Oncol，2012，102(3)：383-387.
[13]MIHARA K，KAIHARA M，SUNAHORI S，et al.Stereotactic body radiotherapy with cyberknifefor liver metastases from colorectal cancer［J］.Gan to Kagaku Ryoho，2015，42(10)：1262-1264.
[14]KATZ AW，CAREY-SAMPSON M，MUHS AG，et al.Hypofractionated stereotactic body radiation therapy(SBRT) for limited hepatic metastases［J］.Int J Radiat Oncol Biol Phys，2007，67(3)：793-798.
[15]AGOLLI L，BRACCI S，NICOSIA L，et al.Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients：Outcomes and prognostic factors after long-term follow-Up［J］.Clin Colorectal Cancer，2017，16(1)：58-64.
[16]HARTFORD AC，GALVIN JM，BEYER DC，et al.American college of radiology(ACR) and american society for radiation oncology(ASTRO) practice guideline for intensity-modulated radiation therapy(IMRT)［J］.Am J Clin Oncol，2012，35(6)：612-617.
[17]NORDLINGER B，VAN CUTSEM E，ROUGIER P，et al.Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the european colorectal metastases treatment group［J］.Eur J Cancer，2007，43(14)：2037-2045.
[18]DEXIANG Z，LI R，YE W，et al.Outcome of patients with colorectal liver metastasis：Analysis of 1 613 consecutive cases［J］.Ann Surg Oncol，2012，19(9)：2860-2868.
[19]KOPETZ S，CHANG GJ，OVERMAN MJ，et al.Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy［J］.J Clin Oncol，2009，27(22)：3677-3683.
[20]ALBERT M，KIEFER MV，SUN W，et al.Chemoembolization of colorectal liver metastases with cisplatin，doxorubicin，mitomycin C，ethiodol，and polyvinyl alcohol［J］.Cancer，2011，117(2)：343-352.
[21]NISHIOFUKU H，TANAKA T，MATSUOKA M，et al.Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure：Results of a phase I/II study［J］.J Vasc Interv Radiol，2013，24(1)：56-65.
[22]VAN DER POOL AE，MENDEZ ROMERO A，WUNDERINK W，et al.Stereotactic body radiation therapy for colorectal liver metastases［J］.Br J Surg，2010，97(3)：377-382.
[23]AMBROSINO G，POLISTINA F，COSTANTIN G，et al.Image-guided robotic stereotactic radiosurgery for unresectable liver metastases：Preliminary results［J］.Anticancer Res，2009，29(8)：3381-3384.
[24]KIM MS，KANG JK，CHO CK，et al.Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer［J］.Tumori，2009，95(4)：449-454.
[25]BEPPU T，MIYAMOTO Y，SAKAMOTO Y，et al.Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases，focusing on conversion hepatectomy and long-term survival［J］.Annals of Surgical Oncology，2014，21(Suppl 3)：S405-413.
[26]潘军，秦叔逵，陈映霞，等.结直肠癌伴同时性肝转移转化为可切除的临床因素分析［J］.临床肿瘤学杂志，2019，24(01)：44-48. PAN J，QIN SK，CHEN YX，et al.Analysis on clinical factors of initial unresectable colorectal cancer with liver metastases converted for resection［J］.Chinese Clinical Oncology，2019，24(01)：44-48.
[27]IM JH，YOON SM，PARK HC，et al.Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area［J］.Liver Int，2017，37(1)：90-100.
[28]LIU Y，YAN J，WANG F，et al.Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients［J］.Oncol Lett，2018，16(5)：5733-5738.

Memo

Memo:
-
Last Update: 2020-11-30